Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.

Learn about respiratory viruses during viral season and how to stay safe. Dr. Matthew Muller discusses COVID-19, RSV, influenza, and more.

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Anne Murray sang Everything Old Is New Again on episode 415 of The Muppet Show, which aired on February 1, 1980 in the United ...

While RSV isn’t any more virulent than the cold, flu or COVID, the same precautions are recommended in order to control its ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

COVID-19 has been more prevalent and has caused more deaths than flu or respiratory syncytial virus (RSV) in the last three years, according to a study on American veterans published Monday in JAMA ...

As influenza and cold cases, including respiratory syncytial virus (RSV) spike in the nation and Nevada, Intermountain Health ...

With the triad of respiratory viruses present in our day-to-day, it is recommended that individuals receive both COVID-19, flu, and occasionally RSV and MPox vaccinations. However, there is a common ...